Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HKPD, unsubscribe in one click. Privacy
HKPD holds $221,841 in cash and short-term investments and burns about $187,901/quarter from operations, an estimated runway of 3.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 69 · High
These factors raise substantial doubts about the Company’s ability to continue as a going concern.20-F, Aug 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HKPD files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HKPD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →